The effect of lactofem on the vaginosis

The effect of lactofem capsule on the treatment of bacterial vaginosis in pregnant women

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090701002114N7

Enrollment

Registered

2020-11-16

Start date

2020-11-14

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bacterial vaginosis infection.

Interventions

Intervention 1: Intervention group: pregnant women who have a bacterial vaginosis infection according to a doctor's examination will be treated with Lactofem oral capsules and will take one capsule da

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Gestational age over 12 weeks Bacterial vaginosis infection

Exclusion criteria

Exclusion criteria: Concomitant infection with Trichomonas or candidiasis Gestational diabetes urinary tract infection Rupture of the amniotic sac Immune system defects Inflammatory bowel disease

Design outcomes

Primary

Measure	Time frame
Bacterial vaginosis. Timepoint: Evaluation of vaginal infection at the beginning of the study and one month after taking Lactofem capsules. Method of measurement: Vaginal examination by physician.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Yari

Khoram-Abad University of Medical Sciences

yari.f@lums.ac.ir+98 66 3312 0133

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026